The North America Cardiac Marker Testing Market would witness market growth of 7.6% CAGR during the forecast period (2022-2028).
Cardiac biomarkers are crucial for the prompt, accurate diagnosis, treatment, and prognosis of the acute coronary syndrome. The myocardial enzymes, a number of myocardial proteins, peptides, and various other substances were among the many biomarkers that were initially studied. The stable molecules known as microRNAs, which can be found in circulation, are the newest addition to the repertoire.
There are four categories that are identified to be involved in the regulation of the circulatory system, and some of them have promise as early and specific markers of cardiac dysfunction and acute coronary syndrome. The use of microRNAs may provide tailored, precise treatment, as in other areas of medicine. Since now, a multifaceted strategy involving various markers for which troponins are required appears to be the optimal course of action.
Cardiac disorders are the primary cause of death in the United States. In the United States, heart disease was the cause of 1 in 5 fatalities in 2020, taking the lives of almost 697,000 people. Heart disease cost the US $229 billion between 2017 and 2018. This covers the cost of prescription medications, medical expenses, and lost wages due to mortality. The high volume of cardiac marker testing would be performed in the North America region due to this increased prevalence of cardiovascular disorders.
The US market dominated the North America Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,149.2 million by 2028.The Canada market is poised to grow at a CAGR of 10.1% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 9.1% during (2022 - 2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End User, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Cardiac Marker Testing Market is Estimated to reach $8.1 Billion by 2028, at a CAGR of 8.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
By Disease
By End User
By Product
By Biomarker Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
